Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Abingdon Health PLC announced on Wednesday that it will provide Boots UK Ltd with rapid lateral flow self-tests to be sold under the Boots own brand label.
The York, England-based lateral flow technology company has developed Iron and Vitamin D deficiency tests which will be made available from spring onwards online and in stores across the UK in partnership with Crest Medical Ltd, a Warrington-based medical supplies company.
Abingdon Chief Executive Officer Chris Yates said: ‘We take immense pride in the quality of our service and ensure a seamless supply of innovative lateral flow self-tests to ensure our partners requirements are met.’
This as a significant step in strengthening the company’s position in a growing market. In 2023 consumer adoption of self-tests was worth $7.90 billion and the lateral flow market is expected to reach $23 billion by 2027.
Abingdon shares were up 12% to 9.52 pence in London on Wednesday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.